(Total Views: 383)
Posted On: 11/04/2021 1:28:28 PM
Post# of 148900
In assessing value to the recent findings in last PR's...looking into the background of those who analyzed the results is important...that being Creativ Microtech, inc. The parent company being (Thermo Fisher Scientific).
Participants..."Those who had FAILED... at least TWO lines of previous therapy"...These results were determined by the LifeTracDX test developed by Creativ Microtech, Inc. to aid as a parallel diagnostic tool in identifying patients that respond to LERONLIMAB.
May 29, 2020, Creativ MicroTech, Inc. ..granted funding from the National Institute of Cancer (NIC) National Institute of Health (NIH) and the Department of Defense for validation studies in 1000 Breast Patients
1000 Lung patients
300 Prostate patients respectively...these guys ate not slouches...the Clinical report came from them...NOT exactly an infomercial.
Participants..."Those who had FAILED... at least TWO lines of previous therapy"...These results were determined by the LifeTracDX test developed by Creativ Microtech, Inc. to aid as a parallel diagnostic tool in identifying patients that respond to LERONLIMAB.
May 29, 2020, Creativ MicroTech, Inc. ..granted funding from the National Institute of Cancer (NIC) National Institute of Health (NIH) and the Department of Defense for validation studies in 1000 Breast Patients
1000 Lung patients
300 Prostate patients respectively...these guys ate not slouches...the Clinical report came from them...NOT exactly an infomercial.
(3)
(0)Scroll down for more posts ▼
